How symptoms differ between men and women during immunotherapy
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study looks at how symptoms during immunotherapy (a cancer treatment that boosts your immune system) may differ between men and women. Researchers will follow people with cancer who are starting immunotherapy to see if men and women report different side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a cancer diagnosis and are about to start immunotherapy (a treatment that uses your immune system to fight cancer) as your first cancer treatment.
- You do not have breast, prostate, testicular, penile, or gynecologic (female reproductive system) cancer.
- You have never received immunotherapy before.
- You are not currently receiving chemotherapy, targeted therapy, or other non-immunotherapy cancer treatments.
- Your doctor expects you to live at least 6 months and you can complete surveys on a computer or tablet.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects blood, stool, and tissue samples from people who have had side effects from immunotherapy (a type of cancer treatment that helps your immune system fight cancer). It aims to learn more about these side effects, so doctors can better manage them in the future.
This study tries to predict who is more likely to get serious side effects from immune checkpoint medicines used for solid tumors. You may help researchers by answering questionnaires before treatment and during follow-up, and by possibly storing sample specimens.
This study uses special cells grown in a lab to understand why some cancer treatments cause side effects. It may help researchers find ways to predict and prevent these side effects in the future.
This study looks at how people’s bodies respond to cancer immunotherapy and why some people get side effects. Your information and lab results may help improve how immunotherapy is managed in the future.
This study watches people with solid tumors who are starting immunotherapy for the first time. It aims to predict and better understand side effects and how well the treatment works, to help doctors manage care more effectively.
This study compares standard dosing schedules of pembrolizumab or nivolumab (two immunotherapy drugs) to see which one causes fewer immune-related side effects. It is for people with solid tumors who are already eligible to receive one of these drugs as part of their standard care.
Hear when a new Hematopoietic and Lymphatic System Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.